Philipp Paul Lobmaier

Dr. Philipp Paul Lobmaier

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2010 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
PLPhilipp Paul Lobmaier
Philipp Paul Lobmaier
MGMichael Gossop
Michael Gossop
HWHelge Waal
Helge Waal
JBJorgen Bramness
Jorgen Bramness

26 April 2010 in European Addiction Research
Verified
Journal Article
Closed access
PDF file
PLPhilipp Paul Lobmaier
Philipp Paul Lobmaier
NKNikolaj Kunøe
Nikolaj Kunøe
MGMichael Gossop
Michael Gossop
TKTormod Katevoll
Tormod Katevoll
HWHelge Waal
Helge Waal
Background:After prison release, offenders with heroin use problems are at high risk of relapse and overdose death. There is a particular need for treatments that can be initiated in prison and continued after release into the community. Methadone maintenance treatment has been shown to reduce heroin use, criminality and mortality. Naltrexone implant treatment has not previously been evaluated in prison settings. Methods:This study compares the effects of naltrexone implants and methadone treatment on heroin and other illicit drug use, and criminality among heroin-dependent inmates after release from prison. Results:Forty-six volunteers were randomly allocated to naltrexone implants or methadone before release. Intention-to-treat analyses showed reductions in both groups in frequency of use of heroin and benzodiazepines, as well as criminality, 6 months after prison release. Conclusions:Naltrexone implants may be a valuable treatment option in prison settings.

23 April 2008 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
PLPhilipp Paul Lobmaier
Philipp Paul Lobmaier
HKH Kornør
H Kornør
NKN Kunøe
N Kunøe
ABA Bjørndal
A Bjørndal

23 September 2010 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
PLPhilipp Paul Lobmaier
Philipp Paul Lobmaier
NKNikolaj Kunøe
Nikolaj Kunøe
MGMichael Gossop
Michael Gossop
HWHelge Waal
Helge Waal

1 June 2016 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
DMDesiree Madah-Amiri
Desiree Madah-Amiri
TCThomas Clausen
Thomas Clausen
PLPhilipp Paul Lobmaier
Philipp Paul Lobmaier
In order to have a substantial impact on overdose prevention, the expansion and scaling-up of overdose prevention with naloxone distribution (OPEND) programs are needed. However, limited literature exists on the best method to train the large number of trainers needed to implement such initiatives. As part of a national overdose prevention strategy, widespread OPEND was implemented throughout multiple low-threshold facilities in Norway. Following a two-hour 'train-the trainer course' staff were able to distribute naloxone in their facility. The course was open to all staff, regardless of educational background. To measure the effectiveness of the course, a questionnaire was given to participants immediately before and after the session, assessing knowledge on overdoses and naloxone, as well as attitudes towards the training session and distributing naloxone. In total, 511 staff were trained during 41 trainer sessions. During a two-month survey period, 54 staff participated in a questionnaire study. Knowledge scores significantly improved in all areas following the training (p<0.001). Attitude scores improved, and the majority of staff found the training useful and intended to distribute naloxone to their clients. Large-scale naloxone distribution programs are likely to continue growing, and will require competent trainers to carry out training sessions. The train-the-trainer model appears to be effective in efficiently training a high volume of trainers, improving trainers' knowledge and intentions to distribute naloxone. Further research is needed to assess the long term effects of the training session, staffs' subsequent involvement following the trainer session, and knowledge transferred to the clients.

14 March 2020 in Health & Justice
Verified
Journal Article
Open access
PDF file
JHJordan Hyatt
Jordan Hyatt
PLPhilipp Paul Lobmaier
Philipp Paul Lobmaier
Medication-Assisted Treatment (MAT) provides an opportunity to address opioid addiction among justice-involved individuals, an often difficult to reach population. This potential has been increasingly recognized by agencies, policymakers and pharmaceutical companies. The result has been a marked increase in the number of drug courts, prisons and agencies in which MAT, notably with long-acting injectable medications, is offered. While this is a positive development, ensuring that vulnerable individuals are in a position voluntarily participation within the complex criminal justice environment is necessary. The unequal authority and agency inherent in the nature of these environments should be recognized. Therefore, rigorous protections, mirroring the goals of the consent processes required for medical or sociobehavorial research, should be employed when MAT is offered to protect individual autonomy.